Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Triple rAAV9 Vector Combinations Encoding Broadly Neutralizing Antibodies Effectively Suppress HIV-1 Infection in

Danila S Leontyev¹, Felix A Urusov¹, Dina V Glazkova¹

¹Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, 119992 Moscow, Russia.

International Journal of Molecular Sciences

|November 27, 2025

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sleep Maintenance Insomnia in Older Adults: Cardiometabolic Comorbidities and Evidence of Antiviral Pathways Activation from Blood Transcriptome and dsRNA Expression Analyses.

International journal of molecular sciences·2026

Same author

Single-Cell RNA-Seq Profiling of Transposable Element Expression in Human Peripheral Blood Cells During Viral Infections.

International journal of molecular sciences·2026

Same author

Identifying a Common Autoimmune Gene Core as a Tool for Verifying Biological Significance and Applicability of Polygenic Risk Scores.

International journal of molecular sciences·2026

Same author

Characterizing the Bat Virome of Vietnam: A Systematic Review of Viral Diversity and Zoonotic Potential.

Viruses·2025

Same author

Genomic Characterization of NDM-1 Producer <i>Providencia stuartii</i> Isolated in Russia.

Antibiotics (Basel, Switzerland)·2025

Same author

A Novel Nanopore-Based Genotyping System for Norovirus GII: Validation and Application to Pediatric Gastroenteritis Cases in Moscow, Russia.

Viruses·2025

Two novel antibody combinations, CombiMab-1 and CombiMab-2, delivered via recombinant adeno-associated virus serotype 9 vectors, effectively protected humanized mice from HIV-1 challenge, preventing viremia and preserving CD4+ T-lymphocyte counts.

Area of Science:

Immunology
Virology
Gene Therapy

Background:

Human Immunodeficiency Virus (HIV) remains a global health challenge.
Developing effective and durable HIV-1 prevention strategies is critical.
Gene therapy offers a novel approach for delivering therapeutic antibodies.

Purpose of the Study:

To evaluate the protective efficacy of two distinct combinations of broadly neutralizing antibodies against HIV-1.
To assess the ability of recombinant adeno-associated virus serotype 9 (rAAV9) vectors to deliver these antibodies.
To determine the impact of antibody treatment on viral load and CD4+ T-lymphocyte counts in a humanized mouse model.

Main Methods:

Humanized mice were established with primary CD4+ T-lymphocytes.
Mice received preventive treatment with rAAV9 vectors encoding CombiMab-1 or CombiMab-2.

Keywords:

10-1074 10E8 AAV vectors CD4+ T-lymphocytes CombiMab-1 CombiMab-2 HIV-1 N6 PGDM1400 VRC07-523 broadly neutralizing antibodies humanized mice passive immunization viral load

More Related Videos

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Related Experiment Videos

Last Updated: Jan 6, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Animals were subsequently challenged with HIV-1.

Viral load (viremia) and CD4+ T-lymphocyte counts were monitored.

Main Results:

Mice treated with CombiMab-1 or CombiMab-2 showed no detectable viremia post-challenge.
Preventive treatment maintained human CD4+ T-lymphocyte counts in treated mice.
Control animals developed viremia and experienced a decline in CD4+ T-lymphocyte counts.

Conclusions:

CombiMab-1 and CombiMab-2 delivered via rAAV9 vectors demonstrate significant protective efficacy against HIV-1 challenge.
This gene therapy approach offers a promising strategy for HIV-1 prevention.
The study highlights the potential of broadly neutralizing antibodies for long-term HIV-1 control.